Background and Aim: Chronic obstructive pulmonary disease (COPD) is frequently underdiagnosed because of the unavailability of spirometers, especially in resource-limited outpatient settings. This study provides real-world evidence to identify optimal approaches for COPD case finding in outpatient settings.

Methods: This retrospective study enrolled individuals who were at risk of COPD (age ≥40 years, ≥10 pack-years, and ≥1 respiratory symptom). Eligible participants were examined using various COPD case-finding tools, namely the COPD Population Screener (COPD-PS) questionnaire, a COPD prediction ($P_{\text{COPD}}$) model, and a microspirometer, Spirobank Smart; subsequently, the participants underwent confirmatory spirometry. The definition and confirmation of COPD were based on conventional spirometry. Receiver operating characteristic curve (ROC), area under the curve (AUC), and decision curve analyses were conducted, and a clinical impact curve was constructed.

Results: In total, 385 participants took part in the study [284 without COPD (73.77%) and 101 with COPD (26.23%)]. The microspirometer exhibited a higher AUC value than did the COPD-PS questionnaire and the $P_{\text{COPD}}$ model. The AUC for microspirometry was 0.908 (95% confidence interval [CI] = 0.87–0.95), that for the $P_{\text{COPD}}$ model was 0.788 (95% CI = 0.74–0.84), and that for the COPD-PS questionnaire was 0.726 (95% CI = 0.67–0.78). Decision and clinical impact curve analyses revealed that a microspirometry-derived FEV1/FVC ratio of <74% had superior clinical utility to the other measurement tools.

Conclusion: The $P_{\text{COPD}}$ model and COPD-PS questionnaire were useful for identifying symptomatic patients likely to have COPD, but microspirometry was more accurate and had higher clinical utility. This study provides real-world evidence to identify optimal practices for COPD case finding; such practices ensure that physicians have convenient access to up-to-date evidence when they encounter a symptomatic patient likely to have COPD.

Keywords: COPD, COPD case-finding, $P_{\text{COPD}}$ model, COPD-PS questionnaire, microspirometry, spirometry

Introduction

Chronic obstructive pulmonary disease (COPD) is incurable but treatable. It is characterized by airway limitation and respiratory symptoms including dyspnea, chronic cough, and sputum production. COPD is the third leading cause of death worldwide and imposes a substantial economic and social burden. Furthermore, COPD remains largely underdiagnosed, and undiagnosed COPD is associated with unfavorable health outcomes. Undiagnosed COPD is a considerable challenge for health-care systems, and patients with undiagnosed COPD have a heightened risk of exacerbations and mortality.
risk of early death. Increasing evidence supports the benefits of routine pharmaceutical treatment for the early stages of COPD; such benefits include reduced risk and severity of exacerbations, improved overall health, and slow disease progression. Therefore, identifying patients with undiagnosed but clinically significant COPD is imperative.

Spirometry is regarded as the gold standard for COPD diagnosis; nevertheless, the US Preventive Services Task Force recommends against spirometry screening for COPD in asymptomatic adults. Furthermore, despite evidence demonstrating that the underdiagnosis of COPD in primary care settings is a pertinent concern, spirometry is considered unsuitable for screening when resources are lacking owing to the high cost of equipment and the various requirements for appropriate technician training. To overcome these limitations, several COPD case-finding tools have been developed and evaluated. The performance of such tools was summarized in a meta-analysis, which demonstrated that a symptom-based questionnaire, such as the COPD Population Screener (COPD-PS) questionnaire, ensured testing of symptomatic patients with COPD, but microspirometry was more accurate for disease diagnosis. Prediction models are another COPD screening approach. Su et al developed and validated an accurate COPD prediction model, namely the $P_{COPD}$ model, which uses a patient’s age, pack-years, percentage peak expiratory flow rate (PEFR), and COPD assessment test (CAT) score to accurately and rapidly identify at-risk patients with undiagnosed COPD who may require further diagnostic evaluation. Among these validated tools, microspirometry and the $P_{COPD}$ model have been identified as feasible alternative tools for COPD screening in Taiwan.

Meta-analyses have summarized the performance of various COPD case-finding tools, including symptom-based questionnaires and microspirometry. According to such analyses, several limitations remain regarding the heterogeneity in sensitivity and specificity related to patient smoking history, the inclusion of patients diagnosed with COPD, COPD prevalence, and the country in which the tools were used. For example, a study focusing on the COPD-PS questionnaire revealed that this questionnaire had the highest heterogeneity of all COPD case-finding tools, followed by spirometry. Moreover, real-world evidence related to performance assessments of various COPD case-finding tools remains inadequate. Cognizant of these considerations, we conducted a retrospective validation study using a nationwide survey data set to evaluate the performance of 3 COPD case-finding tools, namely the COPD-PS questionnaire, the $P_{COPD}$ model, and microspirometry, in a real-world setting to overcome the aforementioned limitations.

This study provides real-world evidence to identify optimal COPD case-finding practices in outpatient settings and ensures that physicians have improved access to up-to-date evidence when they encounter a symptomatic patient with suspected COPD.

Materials and Methods

Study Design and Procedure

This was a multicenter validation study involving retrospective data analysis. The study protocol and retrospective data analysis procedure for performance assessments of various COPD case-finding tools were approved by the Institutional Review Board of Changhua Christian Hospital (CCH IRB 210709). A flowchart of participant enrollment is presented in Figure 1. Participants were enrolled from 26 outpatient clinics from medical center, regional hospital, and district hospital in Taiwan, and all of the tests undertaken in these settings were completed on the same day. Participants’ demographic information, COPD-PS questionnaire scores, CAT questionnaire scores, microspirometer measurement data, and diagnostic spirometer measurement data were obtained from the relevant clinics. COPD was diagnosed and COPD severity was classified in accordance with GOLD definitions. The reference criterion for COPD was a post-BD FEV1/FVC ratio of <70%, and COPD severity was classified according to the predicted post-BD FEV1 percentage. Data related to all the variables were collected by and stored on an integrated automatic evaluation system, namely the SMART system (Self-Motivated Awareness Respiratory Tele-healthcare; Manifold Health Tech, Zhubei, Taiwan). The collected variables were demographic data; symptoms; FEV1, FVC, and FEV1/FVC ratio (confirmative conventional spirometry); FEV1, FVC, PEFR, and FEV1/FVC ratio (microspirometry); COPD-PS score; and CAT score. The scoring methods of the case-finding tools as listed below:

- COPD-PS questionnaire is a five-item questionnaire that was validated for screening individuals who are...
at high risk of COPD. It is composed of age, smoking history and three COPD-related symptoms (breathlessness, productive cough, and activity limitation). The score ranges from 0 to 10, a cutoff point of 4 has been found to be useful for COPD screening in previous study.16

- The CAT is an eight-item questionnaire that measures the impact of COPD on the patient. It is composed of COPD-related symptoms, including cough, expectoration, dyspnea, chest tightness, confidence in leaving home, limitation of daily activities, the quality of sleep and levels of energy. The score ranges from 0 to 40, with 40 being the most severe impact on health status.17

- The model and the manufacturer of the microspirometer, Spirobank Smart, has been reported in our previous study. In brief, the Spirobank Smart device (Spirobank Smart, MIR, Rome, Italy) is able to connect to smartphone apps through Bluetooth for the seamless recording of lung function parameters. In addition, Spirobank Smart is performed by trained, qualified personnel, including nurse and physician. The best FEV1 and FVC values of 3 attempts to meet ATS/ERS acceptability and repeatability standard.18

- $P_{\text{COPD}}$, a model to identify undiagnosed at-risk patients with COPD. Age, smoking pack-years, CAT score, and percent predicted PEFR) were used for establishing the prediction model. Su et al use the $P_{\text{COPD}}$ for COPD screening among people ages 40 and older with respiratory symptoms and smoking history ($\geq$20 pack-years). And $P_{\text{COPD}} \geq 0.65$ were recommend for identifying subjects at risk of COPD in previous study.13

- The reference criterion for COPD was defined as a postbronchodilator (post-BD) forced expiratory volume in 1s/forced vital capacity less than 0.7 (FEV1/FVC $< 0.70$) determined by confirmative conventional spirometry.1

Study Participants
This study was conducted by the Taiwan Society of Pulmonary and Critical Care Medicine. This society, commissioned by the Taiwan Ministry of Health and Welfare, recruited the participants and conducted the study. This retrospective study used data from Jan 2019 to December 2019. The patient selection criteria and clinical data were presented in a previous article.16 In brief, the inclusion criteria for participants were as follows: being aged $\geq$40 years, reporting $\geq$10 pack-years, presenting with chronic respiratory symptoms (cough, phlegm, or dyspnea, or a combination thereof), and not having a COPD diagnosis. Individuals who did not undergo post-BD spirometry and were unable to correctly operate the microspirometer were excluded. A total of 385 participants completed all of the tests, and their data were analyzed.

Statistical Analysis
Data are presented as percentage and mean ± standard deviation for categorical and continuous variables, respectively. Student’s $t$ test and the chi-square test
were used to compare the differences between the COPD and non-COPD groups. We also calculated the area under the receiver operating characteristic (ROC) curve for the COPD-PS questionnaire, the $P_{COPD}$ model, and a spirometer for diagnosing COPD, with the FEV1/FVC ratio obtained through confirmatory conventional spirometry as the standard. Youden’s index was a statistic which is used to assess the best compromise between the sensitivity and specificity of a test. It was calculated to define the best cut-off point of COPD-PS questionnaire score, $P_{COPD}$ prediction model score, and FEV1/FVC ratio determined by Spirobank Smart for COPD detection in our study population. The sensitivity, specificity, positive predictive values (PPVs), negative predictive values (NPVs), and ROC curve values were subsequently used to evaluate the performance of the screening tools in distinguishing between individuals with and without COPD. Furthermore, we assessed the clinical application of various COPD case-finding tools by using a decision curve analysis and clinical impact curve. Both univariate and multivariate logistic regression analysis were performed to determine the association between potential risk factors and COPD prevalence. In addition, the multivariate logistic regression using the variables found to be statistically significant in univariate analysis with backward stepwise elimination. All statistical analyses were performed using SPSS 22 software (IBM, Armonk, NY, USA) and R software (v.i386 3.6.2; https://www.r-project.org). A two-tailed P value of <0.05 was considered to denote statistical significance.

**Results**

**Patient Characteristics**

The demographic characteristics of the enrolled participants (101 with COPD categorized as the COPD group; 285 without COPD categorized as the non-COPD group) are presented in Table 1. A male preponderance (94.5%) was observed in our study. Compared with the non-COPD group, the COPD group was older, had a lower body mass index, and reported more pack-years. The COPD group had a significantly higher CAT score (12 ± 1), COPD-PS questionnaire score (6.2 ± 0.2), and $P_{COPD}$ model score (0.75 ± 0.02) than did the non-COPD group (CAT score: 9 ± 0; COPD-PS questionnaire score: 4.8 ± 0.1; $P_{COPD}$ model score: 0.49 ± 0.03; all P < 0.001). The pre-BD FEV1/FVC ratio determined using spirometry was significantly lower in the COPD group (63.16 ± 1.31) than in the non-COPD group (81.34 ± 0.44; P < 0.001). The COPD group had a lower post-BD FEV1/FVC ratio (58.88 ± 0.90) than the non-COPD group had (post-BD FEV1/FVC ratio: 81.00 ± 0.42). The demographic variables differed significantly between the groups.

**ROC Curves and Diagnostic Accuracy of Various COPD Case-Finding Tools**

The areas under the ROCs and 95% confidence intervals (CIs) of the 3 aforementioned COPD case-finding tools in distinguishing between individuals with and without COPD were as follows: COPD-PS questionnaire (0.908, 95% CI = 0.87–0.95), $P_{COPD}$ model (0.788, 95% CI = 0.74–0.84), and pre-BD FEV1/FVC ratio determined using microspirometry (0.726, 95% CI = 0.67–0.78; Figure 2).

**Clinical Application of Various COPD Case-Finding Tools**

The related decision curves are illustrated in Figure 3A. The net benefit of microspirometry was greater than that of the COPD-PS questionnaire and $P_{COPD}$ model in terms of threshold probability. Microspirometry had marginally better prediction performance than the other tools had. The clinical impact curves for the 3 COPD case-finding tools are illustrated in Figure 3B–D. These curves reveal the estimated numbers of participants deemed to be at a high risk of adverse outcomes, and the true positive value was in the range of 0.0 to 1.0. For example, at a 20% risk threshold, out of 1000 patients screened, approximately 400 would be deemed high risk through microspirometry analysis and >400 would be deemed high risk using the $P_{COPD}$ model and COPD-PS questionnaire. Approximately 300 of these true COPD cases were identified using all 3 of the models. The results suggested that microspirometry is superior to the other tools.

**Threshold Values and Corresponding Predictive Performance of Various COPD Case-Finding Tools**

The corresponding predictive performance levels of various COPD case-finding tools are presented in Table 2.
According to Youden’s index related to the ROC analysis, a spirometry-derived FEV1/FVC ratio of <74% for a patient at high risk for COPD had the best predictive performance [area under the curve (AUC): 0.871 (0.78–0.89), sensitivity: 84.20%, specificity: 90.14%, PPV: 75.22%, and NPV: 94.12%]. Although a P_COPD score of ≥0.74 had a high specificity, its sensitivity was lower than that of microspirometry and the COPD-PS.

### Table 1 Participant Demographics and Characteristics

| Variables          | Non-COPD | COPD    | Total | P-value |
|--------------------|----------|---------|-------|---------|
| Sample size        | 284      | 101     | 385   | –       |
| **Gender**         |          |         |       |         |
| Male               | 270 (95.1%) | 94 (93.1%) | 364 (94.3%) | 0.447 |
| Female             | 14 (4.9%) | 7 (6.9%) | 21 (5.5%) |         |
| **Age**            |          |         |       |         |
| <55                | 88 (31.0%) | 13 (12.9%) | 101 (26.2%) | <0.0001 |
| 55–60              | 55 (19.4%) | 12 (11.9%) | 67 (17.4%) |         |
| 61–65              | 60 (21.1%) | 17 (16.8%) | 77 (20.0%) |         |
| >65                | 81 (28.5%) | 59 (58.4%) | 140 (36.4%) |         |
| **BMI**            | 25.81±0.23 | 24.22±0.40 | 25.39±0.20 | <0.0001 |
| **Smoke pack year**| 39.90±1.60 | 48.70±2.90 | 42.2±1.50 | 0.008   |
| < 50               | 221 (77.8%) | 59 (58.4%) | 280 (72.2%) | <0.0001 |
| ≥ 50               | 63 (22.2%) | 42 (41.6%) | 105 (27.3%) |         |
| **CAT**            | 9±0      | 12±1    | 10±0  | <0.0001 |
| 0–10               | 191 (67.3%) | 47 (46.5%) | 238 (61.8%) | 0.002   |
| 11–20              | 79 (27.8%) | 42 (41.6%) | 121 (31.4%) |         |
| 21–30              | 13 (4.6%) | 11 (10.9%) | 24 (6.2%) |         |
| 31–40              | 1 (0.4%) | 1 (1.0%) | 2 (0.5%) |         |
| **COPD-PS**        | 4.8±0.1  | 6.2±0.2 | 5.2±0.1 | <0.0001 |
| 1–5                | 190 (67.4%) | 36 (35.6%) | 226 (59.0%) | <0.0001 |
| 6–10               | 92 (32.6%) | 65 (64.4%) | 157 (41.0%) |         |
| **P_COPD**         | 0.49±0.03 | 0.75±0.02 | 0.56±0.02 | <0.0001 |
| **Mobile FEV1/FVC**| 81.34±0.44 | 63.16±1.31 | 76.57±0.62 | <0.0001 |
| **Post-BD FEV1/FVC**| 81.00±0.42 | 58.88±0.90 | 75.20±0.63 | <0.0001 |
| **Severity**       |          |         |       |         |
| GOLD 1             |          | 24 (23.8%) |       | <0.0001 |
| GOLD 2             |          | 53 (52.5%) |       |         |
| GOLD 3             |          | 21 (20.8%) |       |         |
| GOLD 4             |          | 3 (3.0%) |       |         |
questionnaire, A COPD-PS score of ≥5 had a higher AUC value (0.64) than had a COPD-PS score of ≥4 (0.599) but had low sensitivity and specificity for identifying COPD. Compared with the other COPD case-finding measures, a microspirometry-derived FEV1/FVC ratio of <74% achieved the best balance between sensitivity and specificity and also had the highest predictive ability.
Associations of FEV1/FVC Ratio Determined Using Various Case-Finding Tools and Participant Variables with COPD Prevalence

Age, reporting ≥50 pack-years, and CAT category were positively associated with COPD prevalence; relevant details are listed in Table 3. After multivariate adjustments, we observed that a microspirometry-derived FEV1/FVC ratio of <74% (odds ratio [OR] = 43.88; 95% CI = 21.34–90.21), PCOPD score of ≥0.74 (OR = 4.91; 95% CI = 2.81–8.55), and COPD-PS score of ≥5 (OR = 2.76; 95% CI = 1.45–5.27) remained significantly associated with COPD prevalence.

Discussion

The principal findings of this study are as follows: First, in terms of performance and clinical utility, microspirometry was better than the PCOPD model and COPD-PS questionnaire. Second, the optimal FEV1/FEV6 ratio threshold determined through microspirometry was 74%, that of the PCOPD model was 0.735, and that of the COPD-PS questionnaire was 5. Third, patients with a microspirometry-determined FEV1/FEV6 ratio of <74% (OR = 43.88; 95% CI = 21.34–90.21), PCOPD score of ≥0.74 (OR = 4.91; 95% CI = 2.81–8.55), and COPD-PS score of ≥5 (OR = 2.76; 95% CI = 1.45–5.27) remained significantly associated with COPD prevalence.

The 5-item symptom-based COPD-PS questionnaire is used to identify individuals that likely have COPD. This is the first study conducted in Taiwan to validate the use of this questionnaire for the early detection of COPD among asymptomatic participants. Although, traditional spirometry is the gold standard for diagnosing COPD, it remains underused or unavailable in primary care settings or non-specialized areas due to time-consuming procedures, labor-intensive, and requires well-trained professionals for its execution. Microspirometry is a lightweight and cheap device, that has the advantages of user-friendly, time-saving features, the requirement of less patient effort, and which render them useful for COPD early detection. However, the aforementioned studies differed from the present study in that they used FEV1/FEV6 ratio instead of FEV1/FVC ratio. Consequently, a further comparative study that examines the performance differences between FEV1/FEV6 ratio and FEV1/FVC ratio for determining COPD using microspirometry in symptomatic smokers is required. Studies have reported that lower education levels in women, older age, and a prior diagnosis of asthma are associated with an increased risk of COPD among never smokers, suggesting that symptomatic never smokers should be included in clinical surveillance and screening efforts related to COPD. Evidence on the feasibility of microspirometry screening for COPD among symptomatic never smokers remains unclear; further investigation is thus required. Compared with conventional spirometry, microspirometry is a less expensive and more convenient tool for diagnosing COPD in symptomatic smokers.

Table 2: Sensitivity, Specificity, PPV, NPV, and Area Under the Receiver Operating Curve for Spirometry, the PCOPD Model, and the COPD-PS Questionnaire

| Cut Point for Different Tools | Sensitivity | Specificity | PPV | NPV | AUROC (95% CI) |
|-----------------------------|-------------|-------------|-----|-----|---------------|
| Mobile spirometer: FEV1/FVC ≤ 74% | 84.20% | 90.14% | 75.22% | 94.12% | 0.871 (0.78–0.89) |
| PCOPD ≥ 0.74 | 66.30% | 79.23% | 53.17% | 86.87% | 0.728 (0.67–0.79) |
| COPD-PS score ≥ 5 | 83.20% | 45.07% | 35.00% | 88.28% | 0.641 (0.58–0.70) |

International Journal of Chronic Obstructive Pulmonary Disease 2021:16
https://doi.org/10.2147/COPD.S339340

Dovepress

Chen et al

Powered by TCPDF (www.tcpdf.org)
| Variables                        | Crude OR (95% CI) | P-value | Adjusted OR (95% CI) | P-value | Adjusted OR (95% CI) | P-value | Adjusted OR (95% CI) | P-value |
|---------------------------------|-------------------|---------|----------------------|---------|----------------------|---------|----------------------|---------|
| **Gender, Male**                |                   |         |                      |         |                      |         |                      |         |
|                                 | 0.70 (0.27–1.78)  | 0.449   | 0.461 (0.116–1.827)  | 0.271   | 0.55 (0.19–1.61)     | 0.275   | 0.50 (0.18–1.43)     | 0.196   |
| **Age category**                |                   |         |                      |         |                      |         |                      |         |
| <55                             |                   |         |                      |         |                      |         |                      |         |
| 55–60                           | 1.48 (0.63–3.47)  | 0.371   | 2.32 (0.715–7.525)   | 0.161   | 1.33 (0.51–3.43)     | 0.561   | 1.57 (0.63–3.93)     | 0.334   |
| 61–65                           | 1.92 (0.87–4.24)  | 0.108   | 3.62 (1.16–11.27)    | 0.026   | 1.47 (0.60–3.60)     | 0.401   | 1.39 (0.58–3.36)     | 0.463   |
| >65                             | 4.93 (2.52–9.66)  | <0.0001 | 5.46 (2.05–14.53)    | 0.001   | 2.85 (1.30–6.23)     | 0.009   | 3.23 (1.51–6.89)     | 0.002   |
| **Smoke pack year**            |                   |         |                      |         |                      |         |                      |         |
| < 50                            |                   |         |                      |         |                      |         |                      |         |
| ≥ 50                            | 2.50 (1.54–4.05)  | <0.0001 | 1.22 (0.56–2.63)     | 0.620   | 1.66 (0.92–2.98)     | 0.09    | 2.35 (1.35–4.09)     | 0.003   |
| **BMI**                         |                   |         |                      |         |                      |         |                      |         |
| 0.89 (0.84–0.95)                | 0.001             |         | 0.94 (0.85–1.03)     | 0.169   | 0.89 (0.82–0.95)     | 0.001   | 0.89 (0.83–0.95)     | 0.001   |
| **CAT category**                |                   |         |                      |         |                      |         |                      |         |
| 0–10                            |                   |         |                      |         |                      |         |                      |         |
| 11–20                           | 2.16 (1.32–3.53)  | 0.002   | 1.70 (0.80–3.62)     | 0.164   | 1.93 (1.09–3.42)     | 0.024   | 1.98 (1.13–3.45)     | 0.016   |
| 21–30                           | 3.44 (1.45–8.16)  | 0.005   | 3.12 (0.89–10.90)    | 0.740   | 2.16 (0.77–6.07)     | 450.1   | 2.76 (1.02–7.47)     | 0.045   |
| 31–40                           | 4.06 (0.25–66.17) | 0.325   | 7.06 (0.07–74)       | 0.410   | 3.29 (0.10–111.90)   | 0.508   | 4.72 (0.16–143.30)   | 0.373   |
| **Mobile spirometer: FEV1/FVC ≤ 74%** | 48.57 (25.07–94.11) | <0.0001 | 43.88 (21.94–90.21)  | <0.0001 |                      |         |                      |         |
| **PCOPD ≥ 0.74**                |                   |         |                      |         |                      |         |                      |         |
| 7.51 (4.55–12.42)               | <0.0001           |         | 4.91 (2.82–8.55)     | <0.0001 |                      |         |                      |         |
| **COPD-PS score ≥ 5**           |                   |         |                      |         |                      |         |                      |         |
| 4.05 (2.29–7.18)                | <0.0001           |         |                      |         |                      |         |                      |         |
that for a US population (AUC = 0.65). The reason for such differences is unclear, but participant backgrounds, study settings, and differences between countries may have affected the thresholds and performance of the COPD-PS questionnaire. In our study, despite the low specificity and PPV at thresholds of 4 or 5, the NPV was sufficiently high; this finding indicates that the COPD-PS questionnaire with a threshold of 4 or 5 is a useful screening tool. Moreover, a simple and self-scored tool, such as the COPD-PS questionnaire, for patient screening may lead to increased awareness, earlier symptom recognition, and the use of conventional spirometry for accurate diagnosis. Therefore, the COPD-PS questionnaire is useful for COPD screening because it can more expediently identify symptomatic patients compared with microspirometry; this expediency is crucial in resource-constrained settings and for routine patient monitoring.

The combination of a peak expiratory flow (PEF) device and a questionnaire has been investigated in relevant studies. Several test combinations have been proposed in COPD diagnostic research, including the PCOPD model, the CAPTURE model, and a new point-system analysis that incorporates handheld flow meter measurement with an international primary care airway group questionnaire. In these studies, the combination of a questionnaire and PEF device achieved diagnostic performance superior to that of a PEF device alone. Studies have indicated an optimal threshold of 0.65 for the PCOPD model, with high specificity indicated (90%). However, our finding demonstrated that a threshold of 0.65 resulted in a lower specificity (65.85%) and a smaller area under the ROC curve (0.710) compared with a threshold of 0.74. This difference may have been caused by variations in inclusion criteria. Moreover, the present study was a nationwide study, whereas patients from a single medical center and a single specialist site were included in the aforementioned studies. Furthermore, standard instructions regarding how to use a peak flow meter and other devices may influence the measurement and diagnostic accuracy of PEFR in various clinical settings. Although COPD case-finding with a questionnaire and a PEF device has been deemed practical despite the aforementioned parameter differences, a microspirometry-derived FEV1/FVC ratio of <0.74 outperformed the PCOPD in our study. COPD case-finding through a combination of a questionnaire and microspirometry has been suggested to be suitable for use in health-care settings. Studies have demonstrated that a dual-combination assessment tool, namely VitalQPlus, which incorporates the COPD-PS questionnaire and the COPD-6 screener with an FEV1/FEV6 ratio of <75%, could be used by physicians to identify individuals at risk of COPD and to select patients for conventional spirometry. This observation is similar to that in a meta-analysis; the authors of that meta-analysis suggested using a questionnaire as a prescreening test for microspirometry to improve COPD screening accuracy. However, the prescreen use of a COPD-PS questionnaire followed by microspirometry with FEV1/FVC ratio calculations has not been validated and requires further investigation.

The GOLD criteria may underestimate and overestimate disease prevalence in young and older adults, respectively. Although the lower limit of normal (LLN) measurement has been suggested to aid in COPD diagnosis, LLN-based criteria for diagnosing COPD may lead to COPD underdiagnosis in symptomatic patients. Furthermore, the LLN-based criteria generated more false negatives than did the conventional GOLD criteria; these false negatives led to the undertreatment of patients with COPD during different disease stages (eg, GOLD I and II). Additionally, LLN-based criteria tend to categorize elderly individuals with mild obstruction as not having COPD. In our study design, we used a case-finding strategy based on symptom screening. The conventional GOLD definition may therefore be the appropriate choice for reducing COPD underdiagnosis according to our screening strategy. Therefore, we suggest that instead of the conventional GOLD measure, an FEV1/FVC ratio of <0.74 be used along with microspirometry for optimal threshold determination. This optimal threshold resulted in an ideal balance between false positive and false negative results for our study population, thereby reducing the possibility of misdiagnosis.

This study has some limitations. First, retrospective data were collected from a limited number of participants receiving treatment in hospital-based facilities; thus, such individuals may not reflect the entire COPD population. Further evaluation of these alternative COPD case-finding tools is required in primary care settings to expand the tools’ generalizability. Second, the number of participants from primary care settings was smaller than that from hospital settings; this discrepancy might have limited the generalizability of our findings to various outpatient settings. Third, a considerable proportion of the nonsmoking population may exhibit COPD symptoms; consequently, future studies evaluating environmental risk exposure,
such as from secondhand smoke or ambient particulate matter, may be of interest.

We evaluated the performance and clinical utility of 3 COPD case-finding tools in real-world settings. Microspirometry is the most accurate alternative to conventional spirometry. The $P_{\text{COPD}}$ model and COPD-PS questionnaire are useful for identifying symptomatic patients likely to have COPD. The COPD-PS questionnaire is recommended as a pretest for microspirometry. High specificity may be required when selecting the most suitable alternative COPD case-finding tool. Various COPD case-finding tools can offer substantial assistance in resource-limited outpatient settings and enable the earlier detection of symptomatic patients with COPD.

Informed Consent and Patient Details

All procedures performed in present study involving human participants were in accordance with the ethical standards of the Institutional Review Board of Changhua Christian Hospital (Approval number 210709). Written informed consent was not required because of the retrospective nature of the investigation. Patient data confidentiality was maintained, and this study was conducted in accordance with the Declaration of Helsinki.

Funding

The study was funded by Changhua Christian Hospital (grant no:110-CCH-MST-122).

Disclosure

The authors declare no competing interests.

References

1. Global initiative for chronic obstructive lung disease strategy for the diagnosis, management and prevention of COPD 2021. Available from: https://goldcopd.org. Accessed December 7, 2021.
2. Contreras-Garza BM, Xiong W, Guo X, et al. Update on clinical aspects of COPD. N Engl J Med. 2019;381:2484–2486.
3. Diab N, Gershon AS, Sin DD, et al. Underdiagnosis and overdiagnosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;198:1130–1139. doi:10.1164/rccm.201804-0621CI
4. Yawn BP, Martinez FJ. POINT: can screening for COPD improve outcomes? Yes. Chest. 2020;157(1):7–9. doi:10.1016/j.chest.2019.05.034
5. Mannino DM, Thomashow B. COUNTERPOINT: can screening for COPD improve outcomes? No. Chest. 2020;157(1):9–12. doi:10.1016/j.chest.2019.05.035
6. Colak Y, Afzal S, Nordestgaard BG, Vestbo J, Lange P. Prevalence, characteristics, and prognosis of early chronic obstructive pulmonary disease. The Copenhagen General Population Study. Am J Respir Crit Care Med. 2020;201(6):671–680. doi:10.1164/rccm.201908-1644OC
7. Choi JY, Rhee CK. Diagnosis and treatment of early chronic obstructive lung disease (COPD). J Clin Med. 2020;9(11):3426. doi:10.3390/jcm9113426
8. Zhou Y, Zhong NS, Li X, et al. Tiotropium in early-stage chronic obstructive pulmonary disease. N Engl J Med. 2017;377(10):923–935. doi:10.1056/NEJMoa1700228
9. Siu AL, Babbins-Domingo K, Grossman DC, et al.; US Preventive Services Task Force (USPSTF). Screening for chronic obstructive pulmonary disease: US Preventive Services Task Force Recommendation Statement. JAMA. 2016;315(13):1372–1377. doi:10.1001/jama.2016.2638
10. Martinez FJ, O’Connor GT. Screening, case-finding, and outcomes for adults with unrecognized COPD. JAMA. 2016;315(13):1343–1344. doi:10.1001/jama.2016.3274
11. Fujita M, Nagashima K, Takahashi S, Suzuki K, Fujisawa T, Hata A. Handheld flow meter improves COPD detectability regardless of using a conventional questionnaire: a split-sample validation study. Respiratory. 2020;25(2):191–197. doi:10.1113/resp.2018013602
12. Schrieders E, Únal E, Winkler V, et al. Performance of various COPD case-finding tools: a systematic review and meta-analysis. Eur Respir Rev. 2021;30(160):200350. doi:10.1183/16000617.0350-2020
13. Su KC, Ko HK, Chou KT, et al. An accurate prediction model to identify undiagnosed at-risk patients with COPD: a cross-sectional case-finding study. NPJ Prim Care Respir Med. 2019;29(1):22. doi:10.1038/s41533-019-0135-9
14. Haroon S, Jordan R, Takwoingi Y, Adab P. Diagnostic accuracy of screening tests for COPD: a systematic review and meta-analysis. BMJ Open. 2015;5(10):e008133. doi:10.1136/bmjopen-2015-008133
15. Haroon SM, Jordan RE, O’Beirne-Elliman J, Adab P. Effectiveness of case finding strategies for COPD in primary care: a systematic review and meta-analysis, NPJ Prim Care Respir Med. 2015;25:15056. doi:10.1038/npjpirm.2015.56
16. Tsukuya G, Matsumoto K, Fukuyama S, et al.; Hisayama Pulmonary Physiolog Group. Validation of a COPD screening questionnaire and establishment of diagnostic cut-points in a Japanese general population: the Hisayama study. Allergol Int. 2015;64(1):49–53. doi:10.1016/j.alit.2014.06.002
17. Jones PW, Harding G, Berry P, Wijkstra I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Questionnaire. Eur Respir J. 2009;34(3):648–654. doi:10.1183/09031936.00102509
18. Lin CH, Cheng SL, Wang HC, et al. Novel App-based portable spirometer for the early detection of COPD. Diagnostics (Basel). 2021;11(5):785. doi:10.3390/diagnostics11050785
19. Kim JK, Lee CM, Park JY, et al. Active case finding strategy for chronic obstructive pulmonary disease with handheld spirometry. Medicine (Baltimore). 2016;95(50):e5683. doi:10.1097/MD.0000000000005683
20. Represas-Represas C, Fernández-Villar A, Ruano-Raviña A, Priegue-Carrera A, Botana-Rial M; study group of “Validity of COPD-6 in non-specialized healthcare settings”. Screening for chronic obstructive pulmonary disease: validity and reliability of a portable device in non-specialized healthcare settings. PLoS One. 2016;11(1):e0145571. doi:10.1371/journal.pone.0145571
21. Hidalgo Sierra V, Hernández Mezquita MA, Palomo Cobos L, et al. Usefulness of the Piko-6 portable device for early COPD detection in primary care. Arch Bronconeumol (Engl Ed). 2018;54(9):460–466. doi:10.1016/j.arbres.2018.07.008
22. Lamprecht B, McMinnie MA, Vollmer WM, et al.; BOLD Collaborative Research Group. COPD in never smokers: results from the population-based burden of obstructive lung disease study. Chest. 2011;139(4):752–763. doi:10.1378/chest.10-1253
23. Martinez FJ, Raczek AE, Seifer FD, et al.; COPD-PS Clinician Working Group. Development and initial validation of a self-scored COPD Population Screenr questionnaire (COPD-PS). COPD. 2008;5(2):85–95. doi:10.1080/154122550801940721
24. Llordés M, Zurdo E, Vázquez I, Pastrana L, Miravitlles M. Which is the best screening strategy for COPD among smokers in primary care? *COPD*. 2017;14(1):43–51. doi:10.1080/15412555.2016.1239703

25. Miravitlles M, Llor C, Calvo E, Díaz S, Díaz-Cuervo H, Gonzalez-Rojas N. Validación de la versión traducida del Chronic Obstructive Pulmonary Disease-Population Screener (COPD-PS). Su utilidad y la del FEV₁/FEV₆ para el diagnóstico de enfermedad pulmonar obstructiva crónica [Validation of the Spanish version of the Chronic Obstructive Pulmonary Disease-Population Screener (COPD-PS). Its usefulness and that of FEV₁/FEV₆ for the diagnosis of COPD]. *Med Clin (Barc)*. 2012;139(12):522–530. doi:10.1016/j.medcli.2011.06.022

26. Spyratos D, Haidich AB, Chloros D, Michalopoulou D, Sichletidis L. Comparison of three screening questionnaires for chronic obstructive pulmonary disease in the primary care. *Respiration*. 2017;93(2):83–89. doi:10.1159/000453586

27. Sogbetun F, Eschenbacher WL, Welge JA, Panos RJ. A comparison of five surveys that identify individuals at risk for airflow obstruction and chronic obstructive pulmonary disease. *Respir Med*. 2016;120:1–9. doi:10.1016/j.rmed.2016.09.010

28. Londhe J, Apte K, Barne M, Salvi S. CAPTURE: a screening tool for chronic obstructive pulmonary disease or obstructive airway disease? *Am J Respir Crit Care Med*. 2018;197(2):272. doi:10.1164/rccm.201705-1040LE

29. Sui CF, Ming LC, Neoh CF, Ibrahim B. VitalQPlus: a potential screening tool for early diagnosis of COPD. *Int J Chron Obstruct Pulmon Dis*. 2015;10:1613–1622. doi:10.2147/COPD.S84618

30. Smith LJ. The lower limit of normal versus a fixed ratio to assess airflow limitation: will the debate ever end? *Eur Respir J*. 2018;51:1800403. doi:10.1183/13993003.00403-2018

31. Enright P, Brusasco V. Counterpoint: should we abandon FEV₁/FVC <0.70 to detect airflow obstruction? Yes. *Chest*. 2010;138:1040–1042. doi:10.1378/chest.10-2052

32. Güder G, Brenner S, Angermann CE, et al. GOLD or lower limit of normal definition? A comparison with expert-based diagnosis of chronic obstructive pulmonary disease in a prospective cohort-study. *Respir Res*. 2012;13:13. doi:10.1186/1465-9921-13-13

International Journal of Chronic Obstructive Pulmonary Disease

Publish your work in this journal

The International Journal of COPD is an international, peer-reviewed journal of therapeutics and pharmacology focusing on concise rapid reporting of clinical studies and reviews in COPD. Special focus is given to the pathophysiological processes underlying the disease, intervention programs, patient focused education, and self management protocols. This journal is indexed on PubMed Central, MedLine and CAS. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journal